Entheon Announces Termination of Mentis AI Agreement
Entheon Biomedical Corp (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) has announced that Mentis AI (1000141080 Ontario ) has terminated the letter of intent (LOI) dated January 23, 2025. The LOI had outlined the terms for Entheon's proposed acquisition of all issued and outstanding common shares of Mentis AI. This termination follows the company's previous news release dated January 24, 2025.
Entheon Biomedical Corp (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ha annunciato che Mentis AI (1000141080 Ontario) ha terminato la lettera di intenti (LOI) datata 23 gennaio 2025. La LOI delineava i termini per l'acquisizione proposta da Entheon di tutte le azioni ordinarie emesse e in circolazione di Mentis AI. Questa cessazione segue il precedente comunicato stampa dell'azienda datato 24 gennaio 2025.
Entheon Biomedical Corp (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ha anunciado que Mentis AI (1000141080 Ontario) ha rescindido la carta de intención (LOI) con fecha 23 de enero de 2025. La LOI había delineado los términos para la adquisición propuesta por Entheon de todas las acciones ordinarias emitidas y en circulación de Mentis AI. Esta rescisión sigue al comunicado de prensa anterior de la compañía con fecha 24 de enero de 2025.
Entheon Biomedical Corp (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU)는 Mentis AI (1000141080 온타리오)가 2025년 1월 23일자 의향서(LOI)를 종료했다고 발표했습니다. 이 LOI는 Entheon이 Mentis AI의 모든 발행 및 유통 중인 보통주를 인수하기 위한 조건을 설명하고 있었습니다. 이 종료는 2025년 1월 24일자 회사의 이전 보도 자료에 따른 것입니다.
Entheon Biomedical Corp (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) a annoncé que Mentis AI (1000141080 Ontario) a résilié la lettre d'intention (LOI) datée du 23 janvier 2025. La LOI avait défini les termes de l'acquisition proposée par Entheon de toutes les actions ordinaires émises et en circulation de Mentis AI. Cette résiliation fait suite au communiqué de presse précédent de l'entreprise daté du 24 janvier 2025.
Entheon Biomedical Corp (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) hat bekannt gegeben, dass Mentis AI (1000141080 Ontario) das am 23. Januar 2025 datierte Absichtsschreiben (LOI) beendet hat. Das LOI hatte die Bedingungen für die vorgeschlagene Übernahme aller ausgegebenen und ausstehenden Stammaktien von Mentis AI umrissen. Diese Beendigung folgt auf die vorherige Pressemitteilung des Unternehmens vom 24. Januar 2025.
- None.
- Failed acquisition attempt of Mentis AI
- Termination of strategic growth opportunity
Vancouver, British Columbia--(Newsfile Corp. - March 14, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces that, further to its news release dated January 24, 2025, 1000141080 Ontario Ltd. ("Mentis AI") has terminated the letter of intent ("LOI") dated January 23, 2025 which set out the terms whereby Entheon would acquire all of the issued and outstanding common shares in the capital of Mentis AI.
About Entheon Biomedical Corp.
Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.
On Behalf of the Board of Directors,
Timothy Ko, CEO, President and Director
For more information, please contact the Company at:
Entheon Biomedical Corp.
Timothy Ko, CEO
1 (604) 562-3932
timothy@entheonbiomedical.com
https://entheonbiomedical.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/244657
FAQ
What happened to the Entheon Biomedical (ENTBF) and Mentis AI merger agreement?
When was the Entheon Biomedical (ENTBF) and Mentis AI LOI originally announced?
What was the scope of the terminated Entheon (ENTBF) acquisition deal?
Which stock exchanges is Entheon Biomedical listed on?
